Skip to content
Homepage
Author:
Calidi Biotherapeutics, Inc
Posted Date:
July 8, 2026
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
Calidi Biotherapeutics, Inc
July 8, 2026
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Calidi Biotherapeutics, Inc
June 24, 2026
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Calidi Biotherapeutics, Inc
June 23, 2026
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
Calidi Biotherapeutics, Inc
June 16, 2026
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
Calidi Biotherapeutics, Inc
June 8, 2026
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
Calidi Biotherapeutics, Inc
May 26, 2026
Calidi Biotherapeutics Provides Required NYSE American Disclosure
Calidi Biotherapeutics, Inc
May 22, 2026
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics, Inc
May 14, 2026
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
Calidi Biotherapeutics, Inc
May 13, 2026
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
Calidi Biotherapeutics, Inc
April 29, 2026
1
2
3
Next
